Abstract: Borneol derivatives of formula I ##STR1## in which R.sup.1 to R.sup.5 and X.sup.1 to X.sup.2 are defined in the specification, and the method of making the same.

Abstract: The invention concernes borneol esters of general formula (I), in which R.sup.1 means T--C(O)--CH(OR.sup.6)--(NR.sup.7a R.sup.7b)--R.sup.8, C(O)--CH(OR.sup.6a)--CH[NR.sup.7 (C(O)--CH(OR.sup.6b)--CH (NR.sup.7a R.sup.7b)--R.sup.8a)]--R.sup.8b ; R.sup.7a R.sup.7b are identical or different and means R.sup.7 ; R.sup.7 means hydrogen, A, --C(O)R.sup.12, --C(O)OR.sup.12, --C(O)SR.sup.12, --C(O)NHR.sup.9d, --C(O)NR.sup.9d R.sup.9e, --SO.sub.2 R.sup.12, C.sub.1 -C.sub.10 alkyl; R.sup.8a, R.sup.8b are identical or different and mean R.sup.8 ; R.sup.8 means (i), heteroaryl substituted by X.sup.3, C.sub.7 -C.sub.16 aralkyl, alkyl; A is B--[O--(CH.sub.2).sub.t --C(O)].sub.0 or 1-, farnesyl--P(O)(OR.sup.9d)--O--(CH.sub.2).sub.t --C(O)--; B means protein kinase-inhibitors or farnesyl protein transferase-inhibitors such as for example farnesyl (ii); and T is a bond, Z.sup.i or a group (iii). The borneol esters can influence tubulin polymerisation and tubulin depolymerisation.

Abstract: Described are cyclohexanone derivatives of the formula (I), a method of preparing them and intermediates used in their preparation.

Abstract: Compounds of formula I ##STR1## wherein X, R.sup.1, R.sup.2, R.sup.3 and R.sup.4 have the meanings indicated in the description, are described, as well as processes for their production, pharmaceutical preparations containing these compounds as well as their use for treatment of diseases. The compounds have antigestagenic, antiglucocorticoid, antimineralocorticoid and antiandrogenic properties.

Abstract: The invention relates to borneol derivatives of general formula I ##STR1## in which R.sup.1 means C(O)--CH(OR.sup.6)--CH(NHR.sup.7)--R.sup.8,R.sup.2 means hydrogen, --OH, C.sub.1 -C.sub.10 alkyl, C.sub.1 -C.sub.10 alkoxy, --OC(O)R.sup.9a, --OSO.sub.2 R.sup.9a, --OP(O)(OH).sub.2, NHR.sup.9a, NR.sup.9a R.sup.9b,R.sup.3 means hydrogen, --OH, C.sub.1 -C.sub.10 alkoxy, --OC(O)R.sup.9b, --OSO.sub.2 R.sup.9b, --OP(O)(OH).sub.2, orR.sup.2, R.sup.3 together mean an oxygen atom,R.sup.4 means hydrogen, C.sub.1 -C.sub.10 alkyl, --(CH.sub.2).sub.n --OR.sup.11a,R.sup.5 means hydrogen, C.sub.1 -C.sub.10 alkyl, --(CH.sub.2).sub.p --OR.sup.11b, orR.sup.4, R.sup.5 together mean an oxygen atom, a=CHR.sup.10 group,n means 0 to 8,p means 1 to 8,R.sup.7 means --C(O)R.sup.12, --SO.sub.2 R.sup.12, --C(O)OR.sup.12, --C(O)NHR.sup.9d, --C(O)NR.sup.9d R.sup.9e, ##STR2## R.sup.8 means aryl, R.sup.9a-e, R.sup.12 are the same or different and mean C.sub.1 -C.sub.10 alkyl, C.sub.4 -C.sub.8 cycloalkyl, aryl, C.sub.7 -C.sub.16 aralkyl,R.sup.

Abstract: A method of inducing an antigestagenic effect by the administration of compounds of formula I: ##STR1## wherein, substituents are as defined in the specification.

Abstract: The invention relates to vitamin D derivatives, modified in 20-position, of general formula I ##STR1## in which X, Y, Z, R.sub.1, R.sub.2 as well as R.sub.3 have the meaning indicated in the description, process for their production and their use as agents for treatment of hyperproliferative diseases of the skin.

Abstract: New 24-homo vitamin D derivatives of formula I ##STR1## are described, in which R.sup.1 means a hydrogen atom, a hydroxy, an alkanoyloxy group with 1 to 8 carbon atoms or an aralkanoyloxy group with up to 8 carbon atoms,R.sup.2 and R.sup.3, independently of one another, mean a linear or branched alkyl group with 1 to 4 carbon atoms, a trifluoromethyl group or together mean a saturated carbocyclic ring with 3 to 9 carbon atoms formed with carbon atom 25,R.sup.4 and R.sup.5, independently of one another, mean a hydrogen atom, an alkanoyl group with 1 to 8 carbon atoms or an aralkanoyl group with up to 8 carbon atoms, andA and B each mean a hydrogen or together a second bond, andn stands for 1, 2, 3,4 or 5.

Abstract: 22-En-24-a-oxa derivatives in the vitamin D series of general formula I ##STR1## in which R.sup.1, R.sup.2 and R.sup.4, independently of one another, each mean a hydrogen atom, an alkanoyl group with 1 to 9 carbon atoms or an aroyl group,R.sup.3 mean a hydrogen atom each or a linear or branched alkyl group each with 1 to 4 carbon atoms, a trifluoromethyl group each or a saturated or unsaturated carbocyclic or heterocyclic 3-, 4-, 5- or 6-membered ring formed together with the tertiary carbon atom, andX means an alkylene radical --(CH.sub.2).sub.n --with n=1, 2 or 3, process for their production and their pharmaceutical use for treating hyperproliferative diseases are disclosed.

Abstract: The invention relates to vitamin D derivatives, modified in 20-position, of general formula I ##STR1## in which X, Y, Z, R.sub.1, R.sub.2 as well as R.sub.3 have the meaning indicated in the description, process for their production and their use as agents for treatment of hyperproliferative diseases of the skin.

Abstract: The invention discloses side-chain homologous vitamin D derivatives of formula I ##STR1## in which R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6, B, and D have the meanings defined in the specification and either (1) A is a direct bond between carbon atoms 20 and 22 and X is an oxy alkylene radical, --(CH.sub.2).sub.n O-- where n is 1 to 3; (2) A is a methylene bridge, --CH.sub.2 --, between carbon atoms 20 and 22 and X is either an alkylene radical, --(CH.sub.2).sub.n -- or an oxy alkylene radical, --(CH.sub.2).sub.n O--, where n is 1 to 3; or (3) if A is a direct bond and B and D together form a second bond, then X(R.sup.5) (R.sup.6) is ##STR2## The compounds possess proliferation-inhibiting and cell-differentiating activity.

Abstract: A 14.alpha.,17.alpha.-bridged estratriene of formula I ##STR1## wherein (a) OR.sup.3 is in .alpha.-positionR.sup.1, R.sup.2 and R.sup.3, each independently are (i) hydrogen, (ii) ##STR2## in which R.sup.4 is an organic radical with up to 11 carbon atoms or (iii) --(CH.sub.2).sub.n COOH wherein n=1-4, or (iv) R.sup.1 is a benzyl, C.sub.1 -C.sub.8 alkyl or C.sub.3 -C.sub.5 cycloalkyl, or(b) OR.sup.3 is in .beta.-positionR.sup.1, R.sup.2 and R.sup.3, each independently are (i) hydrogen, (ii) an acyl group with 1 to 12 carbon atoms or (iii) R.sup.1 is C.sub.1 -C.sub.8 alkyl, and in both (a) and (b) A--B is an etheno or ethano bridge.

Abstract: 8-En-19,11.beta.-bridged steroids of general formula I ##STR1## that have the 8,9-double bond as a new structural feature, and a process for their production are described. The substituents R.sup.1 R.sup.4 -Y, R.sup.4' -Y.sup.', X and Z have the meaning indicated in the description. The new compounds especially have at their disposal pronounced antigestagen effectivenss and are suitable for the production of pharmaceutical preparations.

Abstract: New 20-methyl-substituted vitamin D derivatives of general formula I ##STR1## are described in whichR.sup.1 means a hydrogen atom, a hydroxy group or an alkanoyloxy group with 1 to 12 carbon atoms or a benzoyloxy group,R.sup.2 means a hydrogen atom or an alkanoyl group with 1 to 12 carbon atoms or a benzoyl group andR.sup.3 means a saturated or unsaturated, straight-chain or branched hydrocarbon radical with up to 18 C atoms, which optionally contains carbocyclic structures, optionally substituted with one or more hydroxy, oxo, amino group(s) and/or one or more halogen atom(s) as well as optionally exhibits one or more oxygen, sulfur and/or nitrogen atom(s) as a bridging link or links in the hydrocarbon radical, and a process for their production.Relative to calcitriol, the new compounds exhibit a greatly improved induction of cell differentiation (HL-60) and are suitable for the production of pharmaceutical agents.

Abstract: A process of cyclizing compounds of formula II ##STR1## wherein K, V', R.sup.1 and 1 are as herein defined, is described whereby a compound of formula IVa is produced ##STR2## wherein K, V', R.sup.1, Q, S and 1 are as herein defined. The compounds of formula IVa are useful intermediates in the production of compounds of formula I ##STR3## wherein ring A, B, G, V, Z, R.sup.1 and R.sup.2 are as herein defined.

Abstract: 20 -Methyl-5,7-pregnadiene-3.beta.,21-diol derivatives of general formula I ##STR1## in which R.sub.1 means a hydrogen atom or a lower alkyl group andR.sub.2 means a lower alkyl group orR.sub.1 and R.sub.2 together represent a tetramethylene group or a pentamethylene group and a process for their production are described.

Abstract: Novel compounds of the general formula I ##STR1## and the pharmacologically tolerable addition salts thereof with acids are described, in which eitherIa) R.sup.11 represents a hydrogen atom in the .beta.-configuration and each of R.sup.12 and R.sup.13 represents a hydrogen atom, orIb) R.sup.11 represents a hydrogen atom in the .beta.-configuration and R.sup.12 and R.sup.13 together represent a second bond, orIc) R.sup.11 and R.sup.12 together represent a second bond and R.sup.13 represents a hydrogen atom, orId) R.sup.11 represents a hydrogen atom in the .alpha.-configuration and R.sup.12 and R.sup.13 together represent a second bond,and in Ia), Ib), Ic) or Id)X represents an oxygen atom, the hydroxyimino grouping >N.about.OH or two hydrogen atoms,R.sup.1 represents a hydrogen atom or a methyl group,R.sup.2 represents a hydroxy group, a C.sub.1 -C.sub.10 -alkoxy group or a C.sub.1 -C.sub.10 -acyloxy group, andR.sup.3 and R.sup.

Abstract: 23-Oxa-derivatives in the vitamin D series of formula I ##STR1## are described in which R.sup.1, R.sup.2 and R.sup.4 independently of one another mean a hydrogen atom or an acyl group with 1 to 9 carbon atoms,R.sup.3 each means a hydrogen atom or each a linear or branched alkyl group with 1 to 4 carbon atoms and X means an alkylene radical--(CH.sub.2).sub.n -- with n=1, 2, 3, and if n=1, R.sup.3 each cannot be a methyl or propyl group, as well as a process for their production.The compounds have proliferation-inhibiting and cell-differentiation effects and are suitable for the production of pharmaceutical agents.

Abstract: A process for the production of 10.beta.-H-11.beta.-(substituted phenyl) steroids of the formulae Ia or Ib set forth in the claims by reduction of a compound of the formula III: ##STR1## followed by cleaving with a strong acid or partial cleaving with a less strong acid. Reduction with an electropositive metal in an electron-solvating solvent is preferred.

Abstract: The invention includes compounds of the following formula ##STR1## where A and B either A and B form an additional double bond and D is a hydrogen atom or B and D form an additional double bond and A is a hydrogen atom and the other variables are as defined in the specification. Also disclosed is a process of making the compounds and a process of using the compounds to make compounds of the following formula ##STR2## where the variables are defined in the specification. These compounds are useful as antigestigens.